Daiichi Sankyo Co’s new influenza drug CS-8958 has been successful in the late stage clinical studies. The company is planning to filing for government approval in Japan by March. The new drug has demonstrated better efficacy and safety in its phase-3 studies as compared with Roche’s Tamiflu, one of the most widely prescribed influenza drugs. CS-8958 also produced better results than Tamiflu in pediatric studies without any serious safety problems, Daiichi Sankyo said. Daiichi Sankyo expects CS-8958 to be also effective for treating swine flu.